ARQ 501 in Subjects With Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-09-30

Study Completion Date

2007-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ARQ 501, an investigational anticancer drug, is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer using the Company's unique biology platform, Activated Checkpoint Therapy™ (ACT).

ARQ 501 has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors

NCT00524524

Advanced Solid Tumors

COMPLETED PHASE1

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

NCT00612209

Cancer, Advanced Solid Tumors

COMPLETED PHASE1

A Study of ARQ 171 in Patients With Advanced Solid Tumors

NCT00398840

Cancer

TERMINATED PHASE1

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

NCT00612703

Cancer

COMPLETED PHASE1

Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

NCT00825487

Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ARQ 501

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed solid tumor that is metastatic, unresectable or recurrent and for which standard curative or palliative measures do not exist or are no longer effective.
* ECOG performance status greater than or equal to 1
* Life expectancy greater than three months
* Acceptable pretreatment clinical laboratory results

Exclusion Criteria

* Subjects who have had chemotherapy or radiotherapy within 4 weeks
* Subjects receiving any other investigational agents
* Subjects with known untreated brain metastases
* Subjects receiving hepatic enzyme-inducing antiseizure drugs ("EIASD")
* Subjects with uncontrolled intercurrent illnesses
* Pregnant women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No